Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 May 31;2013(5):CD004525.
doi: 10.1002/14651858.CD004525.pub2.

Etanercept for the treatment of rheumatoid arthritis

Anne Lethaby  1 , Maria Angeles Lopez-Olivo, Lara Maxwell, Amanda Burls, Peter Tugwell, George A Wells
Affiliations
Meta-Analysis

Etanercept for the treatment of rheumatoid arthritis

Anne Lethaby et al. Cochrane Database Syst Rev. .

Abstract

Background: Etanercept is a soluble tumour necrosis factor alpha-receptor disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).

Objectives: The purpose of this review was to update the previous Cochrane systematic review published in 2003 assessing the benefits and harms of etanercept for the treatment of RA. In addition, we also evaluated the benefits and harms of etanercept plus DMARD compared with DMARD monotherapy in those people with RA who are partial responders to methotrexate (MTX) or any other traditional DMARD.

Search methods: Five electronic databases were searched from 1966 to February 2003 with no language restriction. The search was updated to January 2012. Attempts were made to identify other studies by contact with experts, searching reference lists and searching trial registers.

Selection criteria: All controlled trials (minimum 24 weeks' duration) comparing four possible combinations: 1) etanercept (10 mg or 25 mg twice weekly) plus a traditional DMARD (either MTX or sulphasalazine) versus a DMARD, 2) etanercept plus DMARD versus etanercept alone, 3) etanercept alone versus a DMARD or 4) etanercept versus placebo.

Data collection and analysis: Two review authors independently extracted data and assessed the risk of bias of the trials.

Main results: Three trials were included in the original version of the review. An additional six trials, giving a total of 2842 participants, were added to the 2012 update of the review. The trials were generally of moderate to low risk of bias, the majority funded by pharmaceutical companies. Follow-up ranged from six months to 36 months.BenefitAt six to 36 months the American College of Rheumatology (ACR) 50 response rate was statistically significantly improved with etanercept plus DMARD treatment when compared with a DMARD in those people who had an inadequate response to any traditional DMARD (risk ratio (RR) 2.0; 95% confidence interval (CI) 1.3 to 2.9, absolute treatment benefit (ATB) 38%; 95% CI 13% to 59%) and in those people who were partial responders to MTX (RR 11.7; 95% CI 1.7 to 82.5, ATB 36%). Similar results were observed when pooling data from all participants (responders or not) (ACR 50 response rates at 24 months: RR 1.9; 95% CI 1.3 to 2.8, ATB 29%; 36 months: RR 1.6; 95% CI 1.3 to 1.9, ATB 24%). Statistically significant improvement in physical function and a higher proportion of disease remission were observed in combination-treated participants compared with DMARDs alone ((mean difference (MD) -0.36; 95% CI -0.43 to -0.28 in a 0-3 scale) and (RR 1.92; 95% CI 1.60 to 2.31), respectively) in those people who had an inadequate response to any traditional DMARD. All changes in radiographic scores were statistically significantly less with combination treatment (etanercept plus DMARD) compared with MTX alone for all participants (responders or not) (Total Sharp Score (TSS) (scale = 0 to 448): MD -2.2, 95% CI -3.0 to -1.4; Erosion Score (ES) (scale = 0 to 280): MD -1.6; 95% CI -2.4 to -0.9; Joint Space Narrowing Score (JSNS) (scale = 0 to 168): MD -0.7; 95% CI -1.1 to -0.2), and with combination treatment compared with etanercept alone (TSS: MD -1.1; 95% CI -1.8 to -0.5; ES: MD -0.7; 95% CI -1.1 to -0.2; JSNS: MD -0.5, 95% CI -0.7 to -0.2). The estimate of irreversible physical disability over 10 years given the radiographic findings was 0.45 out of 3.0.When etanercept monotherapy was compared with DMARD monotherapy, there was generally no evidence of a difference in ACR50 response rates when etanercept 10 mg or 25 mg was used; at six months etanercept 25 mg was significantly more likely to achieve ACR50 than DMARD monotherapy but this difference was not found at 12, 24 or 36 months. TSS and ES radiographic scores were statistically significantly improved with etanercept 25 mg monotherapy compared with DMARD (TSS: MD -0.7; 95% CI -1.4 to 0.1; ES: MD -0.7; 95% CI -1.0 to -0.3) but there was no evidence of a statistically significant difference between etanercept 10 mg monotherapy and MTX.HarmsThere was no evidence of statistically significant differences in infections or serious infections between etanercept plus DMARD and DMARD alone at any point in time. Infection rates were higher in people receiving etanercept monotherapy compared with DMARD; however, there were no differences regarding serious infections. For those participants who had an inadequate response to DMARDs, the rate of total withdrawals was lower for the etanercept plus DMARD group compared with DMARD alone (RR 0.53; 95% CI 0.36 to 0.77, ATB 18%). No other statistically significant differences were observed in any of the assessed comparisons.

Authors' conclusions: Etanercept 25 mg administered subcutaneously twice weekly together with MTX was more efficacious than either etanercept or MTX monotherapy for ACR50 and it slowed joint radiographic progression after up to three years of treatment for all participants (responders or not). There was no evidence of a difference in the rates of infections between groups.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study flow diagram.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
1.1
1.1. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 1 ACR50.
1.2
1.2. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 2 ACR70.
1.3
1.3. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 3 Remission (DAS < 2.6).
1.4
1.4. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 4 HAQ (mean improvement from baseline).
1.5
1.5. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 5 Total Sharp Score.
1.6
1.6. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 6 Total withdrawals.
1.7
1.7. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 7 Withdrawals due to adverse events.
1.8
1.8. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 8 Serious adverse events.
1.9
1.9. Analysis
Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 9 Serious Infections.
2.1
2.1. Analysis
Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 1 ACR50.
2.2
2.2. Analysis
Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 2 ACR70.
2.3
2.3. Analysis
Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 3 HAQ (mean reduction from baseline).
2.4
2.4. Analysis
Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 4 Total withdrawals.
2.5
2.5. Analysis
Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 5 Withdrawals due to adverse events.
2.6
2.6. Analysis
Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 6 Serious adverse events.
3.1
3.1. Analysis
Comparison 3 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
3.2
3.2. Analysis
Comparison 3 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
3.3
3.3. Analysis
Comparison 3 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
3.4
3.4. Analysis
Comparison 3 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 DAS.
4.1
4.1. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
4.2
4.2. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
4.3
4.3. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
4.4
4.4. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Remission (DAS < 1.6).
4.5
4.5. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Remission (DAS < 2.6).
4.6
4.6. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 Change in Total Sharp Score (from baseline).
4.7
4.7. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 Change in Erosion Score (from baseline).
4.8
4.8. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
4.9
4.9. Analysis
Comparison 4 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
5.1
5.1. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
5.2
5.2. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR70.
5.3
5.3. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR50.
5.4
5.4. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Remission (DAS < 1.6).
5.5
5.5. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Remission (DAS < 2.6).
5.6
5.6. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 Change in Total Sharp Score (from baseline).
5.7
5.7. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 Change in Erosion Score (from baseline).
5.8
5.8. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
5.9
5.9. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 9 No progression of joint damage.
5.10
5.10. Analysis
Comparison 5 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 10 DAS 28.
6.1
6.1. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
6.2
6.2. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
6.3
6.3. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
6.4
6.4. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Remission (DAS < 1.6).
6.5
6.5. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Remission (DAS < 2.6).
6.6
6.6. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
6.7
6.7. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 Change in Erosion Score (from baseline).
6.8
6.8. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
6.9
6.9. Analysis
Comparison 6 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
7.1
7.1. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 ACR20.
7.2
7.2. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 ACR50.
7.3
7.3. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 ACR70.
7.4
7.4. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Change in Total Sharp Score (from baseline).
7.5
7.5. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Change in Erosion Score (from baseline).
7.6
7.6. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Change in Joint Space Narrowing Score (from baseline).
7.7
7.7. Analysis
Comparison 7 Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 DAS.
8.1
8.1. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 ACR20.
8.2
8.2. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 ACR50.
8.3
8.3. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 ACR70.
8.4
8.4. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Remission (DAS < 1.6).
8.5
8.5. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Remission (DAS < 2.6).
8.6
8.6. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
8.7
8.7. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Change in Erosion Score (from baseline).
8.8
8.8. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 Change in Joint Space Narrowing Score (from baseline).
8.9
8.9. Analysis
Comparison 8 Efficacy at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 No progression of joint damage (TSS ≤ 0.5).
9.1
9.1. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 ACR20.
9.2
9.2. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 ACR50.
9.3
9.3. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 ACR70.
9.4
9.4. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Remission (DAS < 1.6).
9.5
9.5. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Remission (DAS < 2.6).
9.6
9.6. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Change in Total Sharp Score (from baseline).
9.7
9.7. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Change in Erosion Score (from baseline).
9.8
9.8. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 Change in Joint Space Narrowing Score (from baseline).
9.9
9.9. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 No progression of joint damage.
9.10
9.10. Analysis
Comparison 9 Efficacy at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 10 DAS 28.
10.1
10.1. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 ACR20.
10.2
10.2. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 ACR50.
10.3
10.3. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 ACR70.
10.4
10.4. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Remission (DAS < 1.6).
10.5
10.5. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Remission (DAS < 2.6).
10.6
10.6. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Change in Total Sharp Score (from baseline).
10.7
10.7. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Change in Erosion Score (from baseline).
10.8
10.8. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 Change in Joint Space Narrowing Score (from baseline).
10.9
10.9. Analysis
Comparison 10 Efficacy at three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 No progression of joint damage (TSS ≤ 0.5).
11.1
11.1. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
11.2
11.2. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
11.3
11.3. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
11.4
11.4. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 DAS < 3.2.
11.5
11.5. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
11.6
11.6. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 6 EULAR ‐ good response.
11.7
11.7. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 7 EULAR ‐ moderate response.
11.8
11.8. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 8 EULAR ‐ no response.
11.9
11.9. Analysis
Comparison 11 Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 9 DAS.
12.1
12.1. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
12.2
12.2. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
12.3
12.3. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
12.4
12.4. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Remission (DAS < 1.6).
12.5
12.5. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
12.6
12.6. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 6 Change in Total Sharp Score (from baseline).
12.7
12.7. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 7 Change in Erosion Score (from baseline).
12.8
12.8. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
12.9
12.9. Analysis
Comparison 12 Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
13.1
13.1. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
13.2
13.2. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
13.3
13.3. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
13.4
13.4. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Remission (DAS < 1.6).
13.5
13.5. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
13.6
13.6. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
13.7
13.7. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 7 Change in Erosion Score (from baseline).
13.8
13.8. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
13.9
13.9. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
13.10
13.10. Analysis
Comparison 13 Efficacy at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 10 DAS.
14.1
14.1. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
14.2
14.2. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
14.3
14.3. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
14.4
14.4. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Remission (DAS < 1.6).
14.5
14.5. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
14.6
14.6. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
14.7
14.7. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 7 Change in Erosion Score (from baseline).
14.8
14.8. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
14.9
14.9. Analysis
Comparison 14 Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
15.1
15.1. Analysis
Comparison 15 Efficacy at six months: etanercept vs. placebo, Outcome 1 ACR20.
15.2
15.2. Analysis
Comparison 15 Efficacy at six months: etanercept vs. placebo, Outcome 2 ACR50.
15.3
15.3. Analysis
Comparison 15 Efficacy at six months: etanercept vs. placebo, Outcome 3 ACR70.
16.1
16.1. Analysis
Comparison 16 Quality of life at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 HAQ: final value.
16.2
16.2. Analysis
Comparison 16 Quality of life at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 EuroQoL VAS.
17.1
17.1. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Satisfaction with treatment.
17.2
17.2. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 HAQ score after treatment.
17.3
17.3. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 EQ‐5D VAS.
17.4
17.4. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Reduction to normal health assessment (HAQ ≤ 0.5).
17.5
17.5. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Proportion stopping work.
17.6
17.6. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 SF‐36 Physical domain.
17.7
17.7. Analysis
Comparison 17 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 SF‐36 Mental domain.
18.1
18.1. Analysis
Comparison 18 Quality of life at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Percentage improvement in HAQ (from baseline).
18.2
18.2. Analysis
Comparison 18 Quality of life at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 HAQ score after treatment.
19.1
19.1. Analysis
Comparison 19 Quality of life at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 HAQ score: final value.
19.2
19.2. Analysis
Comparison 19 Quality of life at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 EuroQoL VAS.
20.1
20.1. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 HAQ score after treatment.
20.2
20.2. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 HAQ score: change from baseline.
20.3
20.3. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Proportion of participants whose HAQ scores improved from baseline.
20.4
20.4. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 SF‐36 score ‐ physical domain: change from baseline.
20.5
20.5. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Proportion of participants whose SF‐36 (physical) scores improved from baseline.
20.6
20.6. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 SF‐36 score ‐ mental domain: change from baseline.
20.7
20.7. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Proportion of participants whose SF‐36 (mental) scores improved from baseline.
20.8
20.8. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 ASHI: change from baseline.
20.9
20.9. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 Proportion of participants whose ASHI scores improved from baseline.
20.10
20.10. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 10 EQ‐5D VAS.
20.11
20.11. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 11 Satisfaction with treatment.
20.12
20.12. Analysis
Comparison 20 Quality of life at 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 12 Reduction to normal health assessment (HAQ ≤ 0.5).
21.1
21.1. Analysis
Comparison 21 Quality of life at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Percentage improvement in HAQ (from baseline).
21.2
21.2. Analysis
Comparison 21 Quality of life at two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 HAQ score after treatment.
22.1
22.1. Analysis
Comparison 22 Quality of life at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 HAQ score after treatment.
23.1
23.1. Analysis
Comparison 23 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Satisfaction with treatment.
23.2
23.2. Analysis
Comparison 23 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 HAQ score after treatment.
23.3
23.3. Analysis
Comparison 23 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 EQ‐5D VAS.
23.4
23.4. Analysis
Comparison 23 Quality of life at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Reduction to normal health assessment (HAQ ≤ 0.5).
24.1
24.1. Analysis
Comparison 24 Quality of life at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Percentage improvement in HAQ (from baseline).
24.2
24.2. Analysis
Comparison 24 Quality of life at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 HAQ score after treatment.
24.3
24.3. Analysis
Comparison 24 Quality of life at two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Satisfaction with treatment.
25.1
25.1. Analysis
Comparison 25 Quality of life at six months: etanercept vs. placebo, Outcome 1 MOS: mental health (change from baseline).
25.2
25.2. Analysis
Comparison 25 Quality of life at six months: etanercept vs. placebo, Outcome 2 MOS: energy/vitality (change from baseline).
26.1
26.1. Analysis
Comparison 26 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARDs, Outcome 1 Total.
26.2
26.2. Analysis
Comparison 26 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARDs, Outcome 2 Lack of efficacy.
26.3
26.3. Analysis
Comparison 26 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARDs, Outcome 3 Adverse event.
26.4
26.4. Analysis
Comparison 26 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARDs, Outcome 4 Death.
27.1
27.1. Analysis
Comparison 27 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
27.2
27.2. Analysis
Comparison 27 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 Lack of efficacy.
27.3
27.3. Analysis
Comparison 27 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 Adverse events.
27.4
27.4. Analysis
Comparison 27 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Death.
28.1
28.1. Analysis
Comparison 28 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
28.2
28.2. Analysis
Comparison 28 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 Lack of efficacy.
28.3
28.3. Analysis
Comparison 28 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 Adverse event.
28.4
28.4. Analysis
Comparison 28 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Death.
29.1
29.1. Analysis
Comparison 29 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
29.2
29.2. Analysis
Comparison 29 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 Lack of efficacy.
29.3
29.3. Analysis
Comparison 29 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 Adverse event.
29.4
29.4. Analysis
Comparison 29 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Death.
30.1
30.1. Analysis
Comparison 30 Withdrawals six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Total.
30.2
30.2. Analysis
Comparison 30 Withdrawals six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
30.3
30.3. Analysis
Comparison 30 Withdrawals six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Adverse event.
31.1
31.1. Analysis
Comparison 31 Withdrawals 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Total.
31.2
31.2. Analysis
Comparison 31 Withdrawals 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
31.3
31.3. Analysis
Comparison 31 Withdrawals 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Adverse event.
31.4
31.4. Analysis
Comparison 31 Withdrawals 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Death.
32.1
32.1. Analysis
Comparison 32 Withdrawals two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Total.
32.2
32.2. Analysis
Comparison 32 Withdrawals two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
32.3
32.3. Analysis
Comparison 32 Withdrawals two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Adverse event.
32.4
32.4. Analysis
Comparison 32 Withdrawals two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Death.
33.1
33.1. Analysis
Comparison 33 Withdrawals three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Total.
33.2
33.2. Analysis
Comparison 33 Withdrawals three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
33.3
33.3. Analysis
Comparison 33 Withdrawals three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Adverse event.
33.4
33.4. Analysis
Comparison 33 Withdrawals three years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Death.
34.1
34.1. Analysis
Comparison 34 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
34.2
34.2. Analysis
Comparison 34 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
34.3
34.3. Analysis
Comparison 34 Withdrawals six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
35.1
35.1. Analysis
Comparison 35 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
35.2
35.2. Analysis
Comparison 35 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
35.3
35.3. Analysis
Comparison 35 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
35.4
35.4. Analysis
Comparison 35 Withdrawals 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Deaths.
36.1
36.1. Analysis
Comparison 36 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
36.2
36.2. Analysis
Comparison 36 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
36.3
36.3. Analysis
Comparison 36 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
36.4
36.4. Analysis
Comparison 36 Withdrawals two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Deaths.
37.1
37.1. Analysis
Comparison 37 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
37.2
37.2. Analysis
Comparison 37 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
37.3
37.3. Analysis
Comparison 37 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
37.4
37.4. Analysis
Comparison 37 Withdrawals three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Deaths.
38.1
38.1. Analysis
Comparison 38 Withdrawals six months: etanercept vs. placebo, Outcome 1 Total.
38.2
38.2. Analysis
Comparison 38 Withdrawals six months: etanercept vs. placebo, Outcome 2 Lack of efficacy.
38.3
38.3. Analysis
Comparison 38 Withdrawals six months: etanercept vs. placebo, Outcome 3 Adverse event.
39.1
39.1. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
39.2
39.2. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 Abdominal pain.
39.3
39.3. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 Asthenia.
39.4
39.4. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Bone pain/arthralgia.
39.5
39.5. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Bronchitis.
39.6
39.6. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 Diarrhoea.
39.7
39.7. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 Dizziness.
39.8
39.8. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 8 Dyspepsia.
39.9
39.9. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 9 Fever.
39.10
39.10. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 10 Flu syndrome.
39.11
39.11. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 11 Headache.
39.12
39.12. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 12 Hypertension.
39.13
39.13. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 13 Increased cough.
39.14
39.14. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 14 Infection.
39.15
39.15. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 15 Injection site reaction.
39.16
39.16. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 16 Injection site haemorrhage.
39.17
39.17. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 17 Leukopenia.
39.18
39.18. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 18 Miscellaneous skin infections.
39.19
39.19. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 19 Mouth ulcers.
39.20
39.20. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 20 Nausea.
39.21
39.21. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 21 Pain.
39.22
39.22. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 22 Paraesthesia.
39.23
39.23. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 23 Pharyngitis (non‐infectious).
39.24
39.24. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 24 Pharyngitis or laryngitis.
39.25
39.25. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 25 Pruritus.
39.26
39.26. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 26 Rash.
39.27
39.27. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 27 Rhinitis.
39.28
39.28. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 28 Trauma/accidental injury.
39.29
39.29. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 29 Upper respiratory tract infection.
39.30
39.30. Analysis
Comparison 39 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 30 Vomiting.
40.1
40.1. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Nausea.
40.2
40.2. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 Nasopharyngitis.
40.3
40.3. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 Serious infections.
40.4
40.4. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Worsening of rheumatoid arthritis.
40.5
40.5. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Breast cancer.
40.6
40.6. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 Chest pain.
40.7
40.7. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 Pneumonia.
40.8
40.8. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 8 Cholelithiasis.
40.9
40.9. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 9 Invertebral disc protrusion.
40.10
40.10. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 10 Osteoarthritis.
40.11
40.11. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 11 Interstitial lung disease.
40.12
40.12. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 12 Hip arthroplasty.
40.13
40.13. Analysis
Comparison 40 Adverse events within 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 13 Malignancy.
41.1
41.1. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
41.2
41.2. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 Accidental injury.
41.3
41.3. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 Abdominal pain.
41.4
41.4. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 4 Asthenia.
41.5
41.5. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 5 Arthralgia.
41.6
41.6. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 6 Back pain.
41.7
41.7. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 7 Bronchitis.
41.8
41.8. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 8 Diarrhoea.
41.9
41.9. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 9 Dyspepsia.
41.10
41.10. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 10 Flu syndrome.
41.11
41.11. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 11 Gingival/dental infection.
41.12
41.12. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 12 Headache.
41.13
41.13. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 13 Hypertension.
41.14
41.14. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 14 Increase in cough.
41.15
41.15. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 15 Infections (total).
41.16
41.16. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 16 Injection site haemorrhage.
41.17
41.17. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 17 Injection Site Reaction.
41.18
41.18. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 18 Malignancy.
41.19
41.19. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 19 Miscellaneous skin infections.
41.20
41.20. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 20 Nausea.
41.21
41.21. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 21 Pain.
41.22
41.22. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 22 Paraesthesia.
41.23
41.23. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 23 Pharyngitis or laryngitis.
41.24
41.24. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 24 Rash.
41.25
41.25. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 25 Serious infections.
41.26
41.26. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 26 Sinusitis.
41.27
41.27. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 27 Upper respiratory tract infection.
41.28
41.28. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 28 Vomiting.
41.29
41.29. Analysis
Comparison 41 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 29 Worsening of rheumatoid arthritis.
42.1
42.1. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Total.
42.2
42.2. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Alopecia.
42.3
42.3. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Accidental injury.
42.4
42.4. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Asthenia.
42.5
42.5. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Arthralgia.
42.6
42.6. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Bronchitis.
42.7
42.7. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Chest discomfort.
42.8
42.8. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 Dyspepsia.
42.9
42.9. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 Dizziness.
42.10
42.10. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 10 Oedema.
42.11
42.11. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 11 Elevation in alanine transaminase.
42.12
42.12. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 12 Enlargement of lymph nodes.
42.13
42.13. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 13 Fever.
42.14
42.14. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 14 Gastrointestinal symptoms/abdominal pain.
42.15
42.15. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 15 Headache.
42.16
42.16. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 16 Increased blood pressure.
42.17
42.17. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 17 Increased cough.
42.18
42.18. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 18 Infection at another site/pharyngitis or laryngitis, flu syndrome or miscellaneous skin infections.
42.19
42.19. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 19 Injection site haemorrhage.
42.20
42.20. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 20 Injection site reaction.
42.21
42.21. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 21 Insomnia.
42.22
42.22. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 22 Leukopenia.
42.23
42.23. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 23 Nausea.
42.24
42.24. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 24 Pain.
42.25
42.25. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 25 Paraesthesia.
42.26
42.26. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 26 Pharyngitis (non‐infectious).
42.27
42.27. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 27 Pruritus.
42.28
42.28. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 28 Rhinitis.
42.29
42.29. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 29 Skin rash.
42.30
42.30. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 30 Total infectious adverse events.
42.31
42.31. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 31 Upper respiratory tract infection.
42.32
42.32. Analysis
Comparison 42 Adverse events within six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 32 Vision disorder.
43.1
43.1. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Alopecia.
43.2
43.2. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Abdominal pain.
43.3
43.3. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Asthenia.
43.4
43.4. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Back pain.
43.5
43.5. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Diarrhoea.
43.6
43.6. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Dizziness.
43.7
43.7. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Dyspepsia.
43.8
43.8. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 Ecchymosis.
43.9
43.9. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 Headache.
43.10
43.10. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 10 Influenza‐like syndrome.
43.11
43.11. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 11 Injection site haemorrhagia.
43.12
43.12. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 12 Injection site reaction.
43.13
43.13. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 13 Mouth ulcers.
43.14
43.14. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 14 Nausea.
43.15
43.15. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 15 Rash.
43.16
43.16. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 16 Rhinitis.
43.17
43.17. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 17 Sinusitis.
43.18
43.18. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 18 Skin infection.
43.19
43.19. Analysis
Comparison 43 Adverse events within 12 months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 19 Upper respiratory tract infection.
44.1
44.1. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 Total.
44.2
44.2. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 Abdominal pain.
44.3
44.3. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 Asthenia.
44.4
44.4. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 4 Accidental injury.
44.5
44.5. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 5 Arthralgia.
44.6
44.6. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 6 Back pain.
44.7
44.7. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 7 Bronchitis.
44.8
44.8. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 8 Diarrhoea.
44.9
44.9. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 9 Dyspepsia.
44.10
44.10. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 10 Flu syndrome.
44.11
44.11. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 11 Gingival/dental infection.
44.12
44.12. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 12 Headache.
44.13
44.13. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 13 Hypertension.
44.14
44.14. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 14 Increased cough.
44.15
44.15. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 15 Infections (total).
44.16
44.16. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 16 Injection site haemorrhage.
44.17
44.17. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 17 Injection site reaction.
44.18
44.18. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 18 Malignancy.
44.19
44.19. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 19 Miscellaneous skin infections.
44.20
44.20. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 20 Nausea.
44.21
44.21. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 21 Pain.
44.22
44.22. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 22 Paraesthesia.
44.23
44.23. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 23 Pharyngitis or laryngitis.
44.24
44.24. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 24 Rash.
44.25
44.25. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 25 Rheumatoid arthritis.
44.26
44.26. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 26 Serious infections.
44.27
44.27. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 27 Sinusitis.
44.28
44.28. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 28 Upper respiratory tract infection.
44.29
44.29. Analysis
Comparison 44 Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 29 Vomiting.
45.1
45.1. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
45.2
45.2. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 Asthenia.
45.3
45.3. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Blood and lymphatic system disorders/leukopenia.
45.4
45.4. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Dizziness.
45.5
45.5. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 5 Fever.
45.6
45.6. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 6 Flu syndrome.
45.7
45.7. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 7 Gastrointestinal symptoms/abdominal pain/dyspepsia.
45.8
45.8. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 8 Headache.
45.9
45.9. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 9 Hepatobiliary disorders.
45.10
45.10. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 10 Hypertension.
45.11
45.11. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 11 Increased cough.
45.12
45.12. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 12 Infection and infestations/total infectious adverse events.
45.13
45.13. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 13 Injection site reaction/injection site haemorrhage/general disorders and administration site conditions.
45.14
45.14. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 14 Injury, poisoning and procedural complications/accidental Injury.
45.15
45.15. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 15 Malignancy.
45.16
45.16. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 16 Metabolism and nutrition disorders.
45.17
45.17. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 17 Miscellaneous skin infections.
45.18
45.18. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 18 Musculoskeletal and connective tissue disorders/arthralgia.
45.19
45.19. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 19 Nausea.
45.20
45.20. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 20 Nervous system disorders/paraesthesia.
45.21
45.21. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 21 Pain.
45.22
45.22. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 22 Pharyngitis (non‐infectious).
45.23
45.23. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 23 Pharyngitis or laryngitis (infectious).
45.24
45.24. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 24 Reproductive system and breast disorders.
45.25
45.25. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 25 Respiratory, thoracic and mediastinal disorders/bronchitis.
45.26
45.26. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 26 Rhinitis.
45.27
45.27. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 27 Skin and subcutaneous tissue disorders/rash/pruritus.
45.28
45.28. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 28 Total serious adverse events.
45.29
45.29. Analysis
Comparison 45 Adverse events within six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 29 Upper respiratory tract infection.
46.1
46.1. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
46.2
46.2. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 Abdominal pain.
46.3
46.3. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 Accidental injury.
46.4
46.4. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 4 Arthralgia.
46.5
46.5. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 5 Asthenia.
46.6
46.6. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 6 Back pain.
46.7
46.7. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 7 Bronchitis.
46.8
46.8. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 8 Diarrhoea.
46.9
46.9. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 9 Dyspepsia.
46.10
46.10. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 10 Flu syndrome.
46.11
46.11. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 11 Gingival/dental infection.
46.12
46.12. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 12 Headache.
46.13
46.13. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 13 Hypertension.
46.14
46.14. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 14 Increased cough.
46.15
46.15. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 15 Infections (total).
46.16
46.16. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 16 Injection site haemorrhage.
46.17
46.17. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 17 Injection site reaction.
46.18
46.18. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 18 Malignancy.
46.19
46.19. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 19 Miscellaneous skin infections.
46.20
46.20. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 20 Nausea.
46.21
46.21. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 21 Pain.
46.22
46.22. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 22 Paraesthesia.
46.23
46.23. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 23 Pharyngitis or laryngitis.
46.24
46.24. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 24 Rash.
46.25
46.25. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 25 Rheumatoid arthritis.
46.26
46.26. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 26 Serious infections.
46.27
46.27. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 27 Sinusitis.
46.28
46.28. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 28 Upper respiratory tract infection.
46.29
46.29. Analysis
Comparison 46 Adverse events within two years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 29 Vomiting.
47.1
47.1. Analysis
Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 1 Diarrhoea.
47.2
47.2. Analysis
Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 2 Headache.
47.3
47.3. Analysis
Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 3 Injection site reaction.
47.4
47.4. Analysis
Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 4 Rhinitis.
47.5
47.5. Analysis
Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 5 Sinusitis.
47.6
47.6. Analysis
Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 6 Upper respiratory tract infection.
48.1
48.1. Analysis
Comparison 48 Sensitivity analysis: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
48.2
48.2. Analysis
Comparison 48 Sensitivity analysis: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
48.3
48.3. Analysis
Comparison 48 Sensitivity analysis: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
49.1
49.1. Analysis
Comparison 49 Sensitivity analysis: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 1 ACR20.
49.2
49.2. Analysis
Comparison 49 Sensitivity analysis: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 2 ACR50.
49.3
49.3. Analysis
Comparison 49 Sensitivity analysis: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD), Outcome 3 ACR‐70.
50.1
50.1. Analysis
Comparison 50 Sensitivity analysis: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
50.2
50.2. Analysis
Comparison 50 Sensitivity analysis: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
50.3
50.3. Analysis
Comparison 50 Sensitivity analysis: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Bathon 2000 (ERA) {published and unpublished data}
    1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000;343:1586‐93. - PubMed
    1. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al. Health‐related quality of life in early rheumatoid arthritis: impact of disease and treatment response. The American Journal of Managed Care 2002;8(3):231‐40. - PubMed
Combe 2006 {published data only}
    1. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient‐reported outcomes of combination etanercept and sulphasalazine versus etanercept alone in patients with rheumatoid arthritis: a double‐blind randomised 2‐year study. Annals of the Rheumatic Diseases 2009;68(7):1146‐52. [PUBMED: 18794178] - PMC - PubMed
    1. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept European Investigators Network (Etanercept Study 309 Investigators). Etanercept and sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulphasalazine: a double‐blind comparison. Annals of the Rheumatic Diseases 2006;65(10):1357‐62. [PUBMED: 16606651] - PMC - PubMed
Emery 2008 (COMET) {published data only}
    1. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. Lancet 2008;372:375‐82. - PubMed
    1. Emery P, Breedveld FC, Heijde D, Ferraccioli G, Dougados M, Robertson D, et al. Two‐year clinical and radiographic results with combination etanercept‐methotrexate therapy versus monotherapy in early rheumatoid arthritis. Arthritis and Rheumatism 2010;62(3):674‐82. - PubMed
    1. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al. Patient‐reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Annals of the Rheumatic Diseases 2010;69:222‐5. - PubMed
Hu 2009 {published data only}
    1. Hu D, Bao C, Chen S, Gu J, Li Z, Sun L, et al. A comparison study of a recombinant tumour necrosis factor receptor: Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatology International 2009;29:297‐303. - PubMed
Kameda 2010 {published data only}
    1. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Japan Biological Agent Study Integrated Consortium. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomised trial. Modern Rheumatology 2010;20(6):531‐8. [PUBMED: 20574649] - PubMed
Klareskog 2004 (TEMPO) {published data only}
    1. Klareskog L, Heijde D, Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double‐blind randomised controlled trial. Lancet 2004;363:675‐81. - PubMed
    1. Heijde D, Klareskog L, Landewe R, Bruyn GAW, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 2007;56(12):3928‐39. - PubMed
    1. Heijde D, Klareskog L, Rodriguez‐Valverde V, Codreanu C, Bolosiu H, Melo‐Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis and Rheumatism 2006;54(4):1063‐74. - PubMed
    1. Heijde D, Klareskog L, Singh A, Tornero J, Melo‐Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Annals of the Rheumatic Diseases 2005;65:328‐34. - PMC - PubMed
Marcora 2006 {published data only}
    1. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti‐tumour necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. American Journal of Clinical Nutrition 2006;84:1463‐72. - PubMed
Moreland 1999 {published data only}
    1. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health‐related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clinical Therapeutics 2000;22(1):128‐39. - PubMed
    1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Annals of Internal Medicine 1999;130:478‐86. - PubMed
Weinblatt 1999 {published and unpublished data}
    1. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 1999;340:253‐9. - PubMed

References to studies excluded from this review

ACP 2001 {published data only}
    1. Anonymous. Etanercept was more effective and safer than methotrexate in disease progression in early rheumatoid arthritis. ACP Journal club July/August 2001;135(1):22.
Angel 2010 {published data only}
    1. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor‐alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010;55(2):333‐8. - PubMed
Anis 2009 {published data only}
    1. Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 2009;48(10):1283‐9. - PubMed
Benucci 2011 {published data only}
    1. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi‐Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor‐alpha blocking agents in rheumatoid arthritis. International Journal of Immunopathology and Pharmacology 2011;24(1):269‐76. - PubMed
Blank 2009 {published data only}
    1. Blank N, Max R, Schiller M, Briem S, Lorenz HM. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48(4):440‐1. - PubMed
Bliddal 2006 {published data only}
    1. Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, et al. A randomised, controlled study of a single intra‐articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 2006;35(5):341‐5. [PUBMED: 17062431] - PubMed
Boesen 2008 {published data only}
    1. Boesen M, Boesen L, Jensen KE, Cimmino MA, Torp‐Pedersen S, Terslev L, et al. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound‐Doppler show no effect of IA injections in the wrist after 4 weeks. Journal of Rheumatology 2008;35(4):584‐91. [PUBMED: 18322991] - PubMed
Chen 2006 {published data only}
    1. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, et al. Theeffect of etanercept on anti‐cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006;65(1):35‐9. [PUBMED: 15975966] - PMC - PubMed
Cuomo 2006 {published data only}
    1. Cuomo G, Molinaro G, Montagna G, Migliaresi S, Valentini G. A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens. Reumatismo 2006;58(1):22‐5. - PubMed
De Filippis 2006 {published data only}
    1. Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. Panminerva Medica 2006;48(2):129‐35. [PUBMED: 16953150] - PubMed
De Stefano 2010 {published data only}
    1. Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide‐anti‐TNF‐alpha versus methotrexate‐anti‐TNF‐alpha. Clinical Rheumatology 2010;29(5):517‐24. [PUBMED: 20082236] - PubMed
Garnero 2002 {published data only}
    1. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl‐galactosyl‐pyridinoline and type II collagen C‐telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis and Rheumatism 2002;46(1):21‐30. - PubMed
Genovese 2002 {published data only}
    1. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two‐year radiographic and clinical outcomes. Arthritis and Rheumatism 2002;46(6):1443‐50. - PubMed
Genovese 2004 {published data only}
    1. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis and Rheumatism 2004;50(5):1412‐9. [PUBMED: 15146410] - PubMed
Gerlag 2010 {published data only}
    1. Gerlag DM, Hollis S, Layton M, Vencovský J, Szekanecz Z, Braddock M, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis and Rheumatism 2010;62(11):3154‐60. [PUBMED: 20662070] - PubMed
Holman 2008 {published data only}
    1. Holman AJ, Ng E. Heart rate variability predicts anti‐tumour necrosis factor therapy response for inflammatory arthritis. Autonomic Neuroscience 2008;143(1‐2):58‐67. - PubMed
Iwamoto 2009 {published data only}
    1. Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al. Prediction of DAS28‐ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Modern Rheumatology 2009;19(5):488‐92. - PubMed
Johnsen 2006 {published data only}
    1. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomised double blind study. Journal of Rheumatology 2006;33(4):659‐64. - PubMed
Kavanaugh 2008 {published data only}
    1. Kavanaugh A, Klareskog L, Heijde D, Li J, Freundlich B, Hooper M. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Annals of the Rheumatic Diseases 2008;67(10):1444‐7. - PMC - PubMed
Keystone 2004 {published data only}
    1. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomised, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2004;50(2):353‐63. - PubMed
Keystone 2009 {published data only}
    1. Keystone E, Freundlich B, Schiff M, Li J, Hooper M. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. Journal of Rheumatology 2009;36(3):522‐31. - PubMed
Koumakis 2009 {published data only}
    1. Koumakis E, Wipff J, Avouac J, Kahan A, Allanore Y. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti‐tumour necrosis factor‐alpha‐blocking agents. Journal of Rheumatology 2009;36(9):2125‐6. - PubMed
Lan 2004 {published data only}
    1. Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M Jr. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12‐week, double‐blind, randomised, placebo‐controlled study. Journal of the Formosan Medical Association 2004;103(8):618‐23. - PubMed
Lisbona 2008 {published data only}
    1. Lisbona MP, Maymo J, Perich J, Almirall M, Pérez‐García C, Carbonell J. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. Journal of Rheumatology 2008;35(3):394‐7. - PubMed
    1. Lisbona MP, Maymó J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. Annals of the Rheumatic Diseases 2010;69(6):1117‐22. [PUBMED: 20448287] - PubMed
Lukas 2009 {published data only}
    1. Lukas C, Landewé R, Fatenejad S, Heijde D. Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2009;68(11):1691‐5. - PMC - PubMed
Lukas 2010 {published data only}
    1. Lukas C, Heijde D, Fatenajad S, Landewé R. Repair of erosions occurs almost exclusively in damaged joints without swelling. Annals of the Rheumatic Diseases 2010;69(5):851‐5. - PubMed
Lukina 2001 {published data only}
    1. Lukina GV. Double‐blind trial of the effectiveness of antibodies to interferon‐gamma and tumour necrosis factor‐alpha in rheumatoid arthritis (preliminary results). Terapevticheskii Arkhiv 2001;73(5):12‐5. - PubMed
Luzi 2009 {published data only}
    1. Luzi G, Laganà B, Salemi S, Rosa R. Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?. Clinica Terapeutica 2009;160(2):121‐3. - PubMed
Machado 2009 {published data only}
    1. Machado P, Santos A, Pereira C, Loureiro C, Silva J, Chieira C, et al. Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti‐TNFalpha. Bone Spine 2009;76(5):508‐13. - PubMed
Moreland 1997 {published data only}
    1. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)‐Fc fusion protein. New England Journal of Medicine 1997;337(3):141‐7. - PubMed
Moreland 2001 {published data only}
    1. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long‐term safety and efficacy of etanercept in patients with rheumatoid arthritis. Journal of Rheumatology 2001;28(6):1238‐44. - PubMed
Paleolog 1998 {published data only}
    1. Paleolog EM. Modulation of angiogenic vascular endothelial growth factor by tumour necrosis factor alpha and interleukin‐1 in rheumatoid arthritis. Arthritis and Rheumatism 1998;41(7):1258‐65. - PubMed
Roux 2011 {published data only}
    1. Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, Albert C, et al. Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double‐blind, randomised pilot study. Journal of Rheumatology 2011;38(6):1009‐11. [PUBMED: 21406499] - PubMed
Saleem 2009 {published data only}
    1. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al. Disease remission state in patients treated with the combination of tumour necrosis factor blockade and methotrexate or with disease‐modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis and Rheumatism 2009;60(7):1915‐22. - PubMed
Sennels 2008 {published data only}
    1. Sennels H, Sørensen S, Ostergaard M, Knudsen L, Hansen M, Skjødt H, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor‐kappa B ligand, and high‐sensitivity C‐reactive protein in patients with active rheumatoid arthritis randomised to etanercept alone or in combination with methotrexate. Scandinavian Journal of Rheumatology 2008;37(4):241‐7. [PUBMED: 18612923] - PubMed
van Riel 2006 {published data only}
    1. Riel PLC, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus methotrexate alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Annals of the Rheumatic Diseases 2006;65(11):1478‐83. - PMC - PubMed
Weinblatt 2007 {published data only}
    1. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, et al. Selective co stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases 2007;66(2):228‐34. [PUBMED: 16935912] - PMC - PubMed
Weinblatt 2008 {published data only}
    1. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, et al. Efficacy and safety of etanercept 50mg twice a week in patients with rheumatoid arthritis who had a sub‐optimal response to etanercept 50mg once a week. Arthritis and Rheumatism 2008;58(7):1921‐30. - PubMed
Weisman 2007 {published data only}
    1. Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo‐controlled, randomised, double‐blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 2007;46(7):1122‐5. - PubMed

References to ongoing studies

EMPIRE 2006 {unpublished data only}
    1. EMPIRE (Etanercept and Methotrexate in Patients to Induce Remission in Early arthritis). Ongoing study October 2006.
France 2008 {unpublished data only}
    1. An Open‐Label, Randomised Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) Added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity. Ongoing study June 2008.
Japanese 2006 {unpublished data only}
    1. A Randomised, Double‐Blind, Multi‐Centre, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects with Active Rheumatoid Arthritis. Ongoing study June 2006.
Jobanputra 2005 {unpublished data only}
    1. Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept plus Methotrexate plus Steroid with Standard Therapy. Ongoing study December 2005.
Takeuchi 2005 {unpublished data only}
    1. Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan. Ongoing study June 2005.

Additional references

Arnett 1988
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315‐24. - PubMed
Boers 1994
    1. Boers M, Tugwell P, Felson DT. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. Journal of Rheumatology 1994;21:86‐9. - PubMed
Bykerk 2012
    1. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease‐modifying antirheumatic drugs. Journal of Rheumatology 2012;39(8):1559‐82. - PubMed
Donahue 2008
    1. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease‐modifying medications for rheumatoid arthritis. Annals of Internal Medicine 2008;148:124‐34. - PubMed
Felson 1993
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1993;36:729‐40. - PubMed
Felson 1995
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38:727‐35. - PubMed
Fernandez‐Cruz 2008
    1. Fernández‐Cruz E, Alecsandru D, Rodríguez‐Sainz C. Introduction to biological drugs. Actas Dermo‐Sifiliograficas 2008;99 Suppl 4:2‐6. [PUBMED: 19080985] - PubMed
Furst 2007
    1. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Annals of the Rheumatic Diseases 2007;66 Suppl III:iii2‐iii22. - PMC - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jarvis 1999
    1. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57(6):945‐66. [PUBMED: 10400407] - PubMed
Kievit 2007
    1. Kievit W, Fransen J, Oerlemans AJM, Kuper HH, Laar MAFJ, Rooij DJRAM, et al. The efficacy of anti‐TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Annals of the Rheumatic Diseases 2007;66:1473‐8. - PMC - PubMed
Klareskog 2006
    1. Klareskog L, Gaubitz M, Rodriguez‐Valverde V, Malaise M, Dougados M, Wajdula J. A long‐term, open‐label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with disease‐modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2006;65:1578‐84. - PMC - PubMed
Kobelt 2005
    1. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Annals of the Rheumatic Diseases 2005;64:1174‐9. - PMC - PubMed
Lopez‐Olivo 2012
    1. Lopez‐Olivo MA, Tayar JH, Martinez‐Lopez JA, Pollono EN, Cueto JP, Gonzales‐Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy ‐ a meta‐analysis. JAMA 2012;308(9):898‐908. - PubMed
Molenaar 2000
    1. Molenaar E, Heijde D, Boers M. Update on outcome assessment in rheumatic disorders. Current Opinion in Rheumatology 2000;12:91‐8. - PubMed
Moreland 2006
    1. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. Journal of Rheumatology 2006;33:854‐61. - PubMed
Murray 1997
    1. Murray KM, Dahl SL. Recombinant human tumour necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Annals of Pharmacotherapy 1997;31(11):1335‐8. [PUBMED: 9391689] - PubMed
OMERACT 1993
    1. OMERACT. Conference on outcome measures in rheumatoid arthritis clinical trials. Journal of Rheumatology 1993;20:526‐91. - PubMed
Pincus 1993
    1. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis?. Rheumatic Diseases Clinics of North America 1993;19:123‐51. - PubMed
Pincus 1999
    1. Pincus T, Stein CM. ACR 20: clinical or statistical significance?. Arthritis and Rheumatism 1999;42(8):1572‐6. - PubMed
Puolakka 2005
    1. Puolakka K. Work Capacity and Productivity Costs in Early Rheumatoid Arthritis: A Five‐Year Prospective Study [dissertation]. Available from: ethesis.helsinki.fi/julkaisut/laa/kliin/vk/puolakka2/workcapa.pdf (accessed 12 March 2013). Helsinki: Academic Dissertation University of Helsinki, 2005.
Saag 2008
    1. Saag KG, Teng GG, Patkar NM, Anuntiy J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of non‐biologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care and Research 2008;59(6):762‐84. - PubMed
Singh 2009
    1. Singh JA, Christensen R, Wells GA, Suarez‐Almazor ME, Buchbinder R, Lopez‐Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2] - DOI - PMC - PubMed
Singh 2011
    1. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008794.pub2] - DOI - PMC - PubMed
Singh 2012
    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research (Hoboken) 2012;64(5):625‐39. - PMC - PubMed
Smolen 2010a
    1. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux‐Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs. Annals of the Rheumatic Disease 2010;69(6):964‐75. - PMC - PubMed
Smolen 2010b
    1. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage‐related physical disability in rheumatoid arthritis clinical trials. Annals of the Rheumatic Disease 2010;69:1058‐64. [DOI: 10.1136/ard.2009.114652] - DOI - PubMed
Tugwell 2011
    1. Tugwell P, Singh JA, Wells GA. Biologicals for rheumatoid arthritis. BMJ 2011;343:d4027. [DOI: 10.1136/bmj.d4027] - DOI - PubMed
van der Heijde 2005a
    1. Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of the Rheumatic Diseases 2005;64:1582‐7. - PMC - PubMed
van der Heijde 2005b
    1. Heijde D, Landewe R, Klareskog L, Rodriguez‐Valverde V, Settas L, Pedersen R, et al. Presentation and analysis of data on radiographic outcome in clinical trials. Arthritis and Rheumatism 2005;52(1):49‐60. - PubMed
Yazici 2008
    1. Yazici Y, Adler NM, Yazici H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology 2008;47(7):1054‐7. - PubMed
Yee 2003
    1. Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF, West Midlands Rheumatology Services and Training Committee. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti‐tumour necrosis factor therapy: an out‐patient study. Rheumatology (Oxford) 2003;42(7):856‐9. [PUBMED: 12730544] - PubMed

References to other published versions of this review

Blumenauer 2003a
    1. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004525; PUBMED: 14584021] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources